Myelofibrosis – Epidemiology – Epidemiology – Myelofibrosis – Mature Markets

Clarivate Epidemiology’s coverage of myelofibrosis comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United States, France, Germany, Italy, Spain, the United Kingdom, and Japan). We report both the diagnosed incidence and diagnosed prevalence in each country, as well as annualized case counts projected to the national population. All patient populations are forecast for a period of 20 years for the major mature pharmaceutical markets.

Clarivate epidemiology’s myelofibrosis forecast will answer the following questions:

• How will changes in the levels of exposure to known risk or protective factors affect the number of people diagnosed with myelofibrosis per year?
• Of all people diagnosed with myelofibrosis, how many in each of the major mature pharmaceutical markets are drug-treated?
• How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of myelofibrosis over the forecast period?

All forecast data are available on the Clarivate Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.

In addition to the total number of cases of myelofibrosis for each forecast year, Clarivate Epidemiology provides forecast data for the following myelofibrosis patient populations:

• Diagnosed incident cases of primary and secondary myelofibrosis.
• Diagnosed prevalent cases of primary and secondary myelofibrosis.
• Diagnosed incident cases of primary myelofibrosis by biomarker status and comorbidity.
• Diagnosed incident cases of myelofibrosis by International Prognostic Scoring System.
• Diagnosed incident and prevalent cases of myelofibrosis by Dynamic International Prognostic Scoring System.
• Diagnosed incident cases of secondary myelofibrosis by MYSEC-PM model.
• Diagnosed prevalent cases by treatment status.

Note: Coverage may vary by country.